Compare TJX Companies Inc (TJX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TJX Companies Inc vs Viatris Inc — how do they compare? TJX Companies Inc trades at $126.5 (market cap $138.73B), while Viatris Inc trades at $16.5 (market cap $18.95B). The key difference: TJX Companies Inc is far larger — about 7.3× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.91%). Which is the better fit depends on your goals.
| TJX | VTRS | |
|---|---|---|
Market Cap | $138.73B | $18.95B |
Sector | Consumer Cyclical | Health |
52-Week High | $168.41 | $17.86 |
52-Week Low | $126.10 | $9.49 |
Enterprise Value | $147.04B | $31.07B |
Dividend Yield | 1.52% | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TJX Companies trades at $128.91, down 2.4% on the day, with technical indicators showing bearish momentum despite strong fundamentals. The company reported consistent earnings beats in recent quarters with Q2 2026 EPS of $1.22 exceeding the $1.19 estimate. Revenue growth remains robust, climbing from $48.5B in 2022 to $56.4B in 2025, while net margins improved to 8.63%. Recent news highlights TJX's expansion plans, raising its global store target to 7,500 locations.
The investment outlook remains positive given strong analyst support (84.6% buy ratings) and a $169 consensus price target representing 31% upside. However, near-term technical weakness and valuation concerns present risks. The stock's current P/E of 23.87 appears reasonable given the company's 62% ROE and consistent execution, though competitive pressures in off-price retail warrant monitoring.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
